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ABSTRACT 
 
 Our understanding of humoral immune response to human papillomavirus (HPV) 
infection has been mainly derived from studies in women. Very little is known about 
humoral immune response to HPV in men. There is also a growing interest in 
understanding the burden of HPV exposure in the subgroups of the male population, 
including men who have sex with women (MSW), men who have sex with men (MSM) 
and men who have sex with both men and women (MSMW). This dissertation was 
undertaken to understand and characterize humoral immune response, measured by 
detectable serum antibody IgG, to HPV 6, 11, 16 and 18 infection, to estimates 
seroprevalence of HPV 6, 11, 16 and 18, to determine the associations of socio-
demographic and sexual behavioral factors with seroprevalence of individual HPV types, 
and to evaluate the role of serum antibodies in the subsequent acquisition of infection 
with the same HPV type, genetically related and un-related HPV types.  
 Three studies that compose of this dissertation were conducted within the 
framework of two longitudinal studies of HPV infection in men: a single-site natural 
history study of male residents of Tucson, Arizona (the 1st study: N=285); and a multi-
national natural history study of healthy men residing in São Paulo, Brazil, Cuernavaca, 
Mexico, and Tampa, Florida (the 2nd study: N=1477; the 3rd study: N=2187). Men were 
recruited using similar eligibility criteria in both natural history studies and followed every 
6 months for a maximum of 18 months in the single-site study and 48 months in the 
multi-national study. HPV DNA status was assessed using the PGMY09/11 L1 
consensus primer system and the Linear Array HPV Genotyping Protocol. Testing of 
   vi
serum antibodies to HPV 6, 11, 16 and 18 was performed with virus-like particle-based 
ELISA assays. 
Data from our studies indicate that exposure to HPV 6, 11, 16 and 18, the four 
HPV types targeted in the currently license HPV vaccines, is common. Of 285 male 
residents of Tucson, Arizona, 28.8% of them were seropositive to HPV 16 and/or 18 at 
study entry. Similarly, approximately one third of 1477 participants of the multi-national 
male HPV natural history study were seropositive to at least one vaccine HPV type, with 
the percentage of 21.8% in U.S. site, 33.4% in Mexico site, and 49.1% in Brazil site. It is 
also noted that seroprevalence of individual vaccine HPV types is greatly elevated 
among men of different sexual practices. Seroprevalence of HPV 6, 11, 16 and/or 18 
was twice as high among MSM and MSMW compared to MSW. Likewise, 
seroprevalence of individual HPV types was two fold or higher among MSW and MSMW. 
 Our findings suggest that the predominant predictors of seropositivity to HPV 6, 
11, 16 and 18 are age and same-sex sexual behaviors. Seroprevalence increased with 
age among young-to-middle-aged men with significant upward age trends observed for 
HPV 11, 16 and 18. MSM, compared to MSW, more likely to be seropositive to HPV 16 
or 18. Similarly, men who practiced same-sex anal sex, compared to those who did not, 
were significantly more likely to be seropositive to HPV 6, 11, 16 and 18, respectively.  
Among 276 men free of HPV 16 at enrollment in Tucson, We did not detect 
statistically significant associations between the baseline serum antibodies to HPV 16 
and/or 18 and subsequent risk of infection with homogeneous HPV types or related-HPV 
types. Of 2187 men residing in three countries who tested HPV 16 negative at 
enrollment, the risk of subsequent HPV 16 infection was not associated with enrollment 
HPV 16 serum antibodies status. 
Our data provide important estimates of population exposure to vaccine HPV 
types for future studies modeling potential vaccine impact and vaccine cost effectiveness 
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in men. Our findings also support strategic vaccination of males as an effective 
preventive measure for HPV-related diseases and cancers in men and their sex 
partners, men and women alike.  
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CHAPTER 1: 
 
INTRODUCTION 
Human papillomavirus (HPV) infection is one of the most common sexually 
transmitted infections (STIs) in the United States [1]. HPV infection in men contributes 
significantly to infection and subsequent cervical disease in women [2-5]. Studies of HPV 
infection in heterosexual couples have shown that males’ sexual behavior and HPV 
infection status are significantly associated with their female partners’ risk of 
precancerous lesion and cervical cancer [2-8]. High prevalence and high incidence of 
HPV infection in men are also associated with lesions [9-11] and cancers of anal canal 
and penis [12-16]. It has been reported in recent studies [17-19] that 25.8-72.9% of HIV-
negative adult men test positive for genital HPV. Anal and oral HPV, though less 
common, is present in 8.0-16.6% [20-22], and 2.9-7.6% [23] of HIV-negative adult men, 
respectively.  
There is also a growing interest in understanding the burden of HPV infection 
among men with different sexual practices including men who have sex with women 
(MSW), men who have sex with men (MSM) and men who have sex with both men and 
women (MSMW). Compared to MSW, MSM and MSMW are several times more likely to 
be infected with HPV at different anatomic sites, and hence may be at increased risk for 
HPV-associated diseases and cancers [24-28].  
HPV serology reflects cumulative exposures to type-specific HPV over time and 
across anatomic sites. It provides a useful means for estimating cumulative HPV 
exposures in a population and can provide insights into the natural history of HPV 
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infection. With the recent licensure of the quadrivalent HPV vaccine for use in males, 
information on seroprevalence of vaccine-type HPV (HPV 6, 11, 16 and 18) in the 
general male population is needed to provide guidance for strategic planning of 
vaccination.  
Our understanding of humoral immune response to HPV infection has been 
mainly derived from serological studies in women with a focus on serum antibodies to 
HPV 16. In contrast, little is known about humoral immune response to HPV in men. This 
dissertation was undertaken to understand and characterize humoral immune response, 
measured by detectable serum antibody IgG, to HPV 6, 11, 16 and 18 infection, to 
determine the associations of socio-demographic and sexual behavioral factors with 
seroprevalence of individual HPV types, and to evaluate the role of serum antibodies in 
the prevention of subsequent infection with the same HPV type, genetically related and 
un-related HPV types. Three studies were conducted to achieve these objectives. The 
first is a study of serum antibodies to HPV 16 and/or 18, its relationship with potential 
risk factors and subsequent development of HPV 16 and/or 18 infections among a 
cohort of U.S. men; in the second study, investigation of serum antibodies and 
associated risk factors was expanded to four HPV types targeted in current HPV 
vaccines (HPV 6, 11, 16 and 18) among a large multi-national male cohort; and the third 
study further examined if risk of acquiring HPV 16 infection over a three-year follow-up 
period is modified by the enrollment HPV 16 serum antibody status in the same cohort of 
men.  
The sources of study population are two natural history studies of HPV infection 
in men: (1) a single-site, prospective study of male HPV infection conducted between 
September 2003 and December 2005 and funded by the Arizona Disease Control 
Research Commission, consisting of male residents aged 18-44 from Tucson, Arizona; 
(2) an ongoing multi-national prospective study of HPV Infection in Men (HIM Study) 
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beginning in June 2005, comprising men aged 18-70 residing in Tampa, United States, 
São Paulo, Brazil, and Cuernavaca, Mexico.  
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ABSTRACT 
 
Our understanding of humoral response to HPV infection has been mainly 
derived from studies in women. The role of serum antibodies in the natural history of 
HPV in men has yet to be investigated. Data from 285 male participants of a natural 
history study were used to determine epidemiologic factors associated with HPV 16/18 
seropositivity and explore the role of HPV 16 and 18 serum antibodies in subsequent 
HPV infections. Serum antibodies were detected by use of HPV 16 and 18 virus-like 
particles ELISA. Logistic regression and generalized estimating equation was employed 
for evaluation of risk factors. The risk of subsequent HPV infection by baseline antibody 
status was assessed by Incidence Rate Ratio and its confidence intervals. Men aged 36-
44 compared to men aged 18-25 were four times more likely to be seropositive to HPV 
16/18. In addition, being divorced, separated or widowed, being former smoker and 
having sex with men was positively and independently associated with HPV 16/18 
seropositivity. Our findings on the protective role of HPV 16 or 18 serum antibodies in 
subsequent infection were inconclusive. Large prospective studies are warranted to 
adequately address questions on the role of natural immunity in the natural history of 
HPV infections in men. 
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INTRODUCTION 
Type-specific Human Papillomavirus (HPV) serology can provide insights into the 
natural history of HPV infection and associated HPV diseases. Our understanding of 
HPV serology has been mainly derived from studies in women with a focus on serum 
antibodies to HPV 16. A limited number of studies have evaluated the prevalence of 
HPV 16 serum antibodies and its determinants, and fewer have evaluated the 
prevalence of serum antibodies to other HPV types. Among 21 published studies that 
investigated serum antibodies to HPV 16 L1 VLPs and factors associated with HPV 16 
seropositivity, only nine enrolled men [29-37]. Only two published studies to date have 
examined the potential protective role of serum antibodies in subsequent infection in 
women [38, 39] and none have been conducted among men. To address this 
information gap, we investigated epidemiologic factors associated with HPV 16/18 
seropositivity and explored the role of HPV 16 and 18 serum antibodies in subsequent 
HPV infections among 285 U.S. men.  
METHODS 
Study Population. A prospective cohort was established for the HPV Infection 
in Men study in Tucson, Arizona between September 2003 and December 2005. Details 
of this cohort have been reported previously [18, 40]. In brief, 337 men (89.4% of eligible 
men screened) aged 18-44 years were enrolled. Men were residents of southern Arizona 
who reported no prior diagnosis of penile or anal cancers, or genital warts; and no 
current diagnosis or treatment of sexually transmitted infections (STIs) including genital 
warts, genital Herpes, Chlamydia, gonorrhea, syphilis, non-gonococcal urethritis, 
hepatitis B virus, hepatitis C virus and Human Immunodeficiency Virus (HIV) infection. 
All participants were consented prior to enrollment. Men were followed at 6-month 
intervals for approximately 18 months. At each study visit, participants completed a self-
administered risk factor questionnaire, and had penile and scrotal cell samples and a 
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venous blood sample collected. The current analysis included 285 men who completed 
at least 2 study visits, had adequate samples for HPV DNA detection and serum 
antibody testing, and had available questionnaire information from each visit. 
HPV DNA Testing. Cellular materials collected at each visit were tested for 
presence of HPV DNA using the PGMY09/11 L1 consensus primer system. HPV 
genotyping was conducted using the reverse line blot method [41] to detect 37 genital 
HPV types, regardless of the PCR result (Roche Molecular Diagnostics). Only samples 
that tested β-globin positive were deemed adequate and included in this analysis.  
HPV Serum Antibody Testing. HPV VLPs were prepared using BSC-1 cells 
(monkey kidney cell line) infected with the recombinant vaccinia virus expressing the L1 
gene of HPV 16 and 18. IgG antibodies to HPV 16 and 18 VLPs were measured with 
enzyme-linked immunoassay (ELISA) as described previously [42]. Monoclonal 
antibodies used for Capture ELISA were H16.V5-HPV-16 and H18.J4-HPV-18 kindly 
provided by Dr. N. Christensen at Pennsylvania State Medical Center, Hershey, PA. The 
cutpoints were determined using a serum bank from children less than 10 years old with 
no prior history of warts, and calculated as the average reactivity plus two standard 
deviations [42].   
Statistical Analysis.     To determine factors associated with HPV 16/18 serum 
seropositivity, we employed logistic regression models with HPV 16/18 serum antibody 
status as the dependent variable. All participants with available serum antibody 
measurements were included in the analysis regardless of their baseline serum antibody 
status. Repeated measurements taken throughout the study period were incorporated to 
capture changes in serum antibody status. The Generalized Estimating Equation (GEE) 
[43] was applied to account for the correlation between repeated observations of the 
same individuals. An unstructured working correlation was assumed. We examined the 
likelihood of seropositivity in relation to sociodemographic characteristics, such as age, 
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race, marital status, and education; and lifestyle and behavioral factors obtained at 
enrollment, including cigarette smoking, average alcohol use, circumcision, age at first 
sexual intercourse, sexual practice, and lifetime number of sex partners. We also 
included risk factors that changed over time and were repeatedly surveyed at each study 
visit, including the number of recent sex partners, self-reported STI status for self and 
partner since last visit, recent condom use and HPV 16/18 DNA status. Factors 
demonstrating a p-value of 0.10 or smaller in univariable models were included in the 
multivariable models and further evaluated by score chi-squared statistics. Odds Ratio 
(OR) and 95% confidence intervals (CIs) were calculated. The risk of subsequent 
infection with type-specific or group-specific HPV was evaluated among men who were 
DNA negative to corresponding HPV type(s) at study entry, and measured by Incidence 
Rate Ratio (IRR) and its 95% CIs calculated using the method proposed by Rothman 
and Greenland [44].  
RESULTS 
Two hundred and eighty-five men were followed for approximately 18 months. Of 
the 285 men, 153 (53.7%) completed four study visits including the enrollment visit, 87 
(30.5%) completed three visits, and 45 (15.8%) only completed two visits. The median 
duration of follow-up was 15.5 months (range, 3.7–24.7 months) and the median follow-
up interval was 5.3 months. The mean age of the cohort was 29.8 years (SD: 8.1). 
Overall, HPV 16/18 seroprevalence was 28.8% at study entry, and 26.4, 30.0 and 29.8% 
at the 6-, 12- and 18-month visit, respectively. At enrollment, 14.8% of men were 
seropositive to HPV 16, followed by 14.4, 18.9 and 24.8% of men at each follow-up visit. 
The seroprevalence for HPV 18 was 21.1, 18.8, 21.6 and 19.9% throughout the study 
period. 
In crude analyses, HPV 16/18 serum antibody status was significantly associated 
with age, marital status, smoking status, sexual practice and the number of lifetime 
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sexual partners (Table 2.1). Characteristics that remained statistically significantly 
associated with serum antibody status in the final adjusted model included age, marital 
status, cigarette smoking and sexual practice. Compared to men aged 18-25 years, men 
aged 36-44 years were more likely to be seropositive to HPV 16/18 (OR, 4.2, 95% CI: 
2.2-8.1). Divorced, separated or widowed men compared to single men were twice as 
likely to be seropositive to HPV 16/18 (OR, 2.3, 95% CI: 1.02-5.3). Smokers were more 
likely to be seropositive compared with never smokers (former smoker: OR, 2.0, 95% CI: 
1.03-3.9; current smoker: OR, 1.5, 95% CI: 0.8-2.8), although the latter did not reach 
statistical significance. A higher likelihood of seropositivity for men having sex with men 
(MSM) compared to men having sex with women only (MSW) was observed (OR, 2.6, 
95% CI: 1.05-6.7).  
We examined the potential protection that HPV 16 and 18 serum antibodies 
confer against subsequent infection by assessing the risk of infection with homologous 
HPV types over the study period among men who had no detectable HPV DNA of 
interest at the baseline by their baseline serum antibody status (Table 2.2). The risk of 
subsequent infection with HPV 16 among 276 men who had no detectable HPV 16 
infection at study entry did not differ significantly by their baseline HPV 16 serum 
antibody status (IRR, 1.1, 95% CI: 0.3-4.0). Similarly, no statistically significant 
difference in the risk of subsequent infection with HPV 18 was detected between HPV 18 
seropositive and seronegative men at the baseline (IRR, 1.8, 95% CI: 0.2-20.2).  
We also explored the potential cross-protection provided by HPV 16 or 18 
antibodies (Table 2.2). Seropositivity to HPV 16 appeared to be protective against new 
infections with HPV 16-related types (HPV 31, 33, 35, 52, 58 and 67) with an IRR of 0.6 
(95% CI: 0.1-2.6), although the IRR did not achieve statistical significance. Similarly, 
seropositivity to HPV 18 yielded a statistically insignificant IRR of 0.6 (95% CI: 0.2-2.0) 
for infection with HPV 18-related types (HPV 39, 45, 59, 68, and 70). No significant 
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reduction in the risk of subsequent infection with other HPV types was observed for HPV 
16 or 18 seropositive men as compared with seronegative men.  
DISCUSSION 
This is one of few studies to examine factors associated with HPV serum 
antibody status in men and the first study to explore the protective role of serum 
antibodies against future infections in men. In this study the predominant predictor of 
HPV 16/18 seropositivity was age. Men aged 36-44 years were four times more likely to 
be seropositive than men aged 18-25 years. In previous studies, age has been positively 
associated with seroprevalence in both men and women [33, 35, 45-48]. In two studies 
that included participants across a broad age range an inverse U-shaped association 
with age was reported, with seroprevalence peaking at age 35-49 and declining with 
increasing age afterwards [45, 46]. The observed age effect in the current study is likely 
to be a result of cumulative lifetime sexual exposure to HPV infection.  
In the current study, smoking status was significantly associated with HPV 
antibody status in men. Smokers, compared to never smokers, were more likely to be 
HPV 16/18 seropositive. Recent studies of HPV seroprevalence and smoking in men 
have yielded mixed results [31, 34, 48]. No significant association with smoking status or 
tobacco use was found in the studies of Kreimer et al. [31] or Stone et al. [34], while a 
significant association with current smoking was reported by Dunne et al. among male 
residents of two U.S. cities (OR, 1.9, 95% CI: 1.1-3.2) [48]. Our finding is in agreement 
with the suggested immune suppressive effect of tobacco smoking which may facilitate 
persistence of viral infection and result in a higher likelihood of seroconversion for 
smokers [49].    
An important observation from the current study was that MSM and MSMW (men 
who had sex with both men and women) were more likely to be seropositive. Similar 
findings have been reported in other studies. Stone et al. demonstrated that MSM were 
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6 times more likely to be seropositive to HPV 16 [34]. Kreimer et al. reported a significant 
association (OR, 2.9, 95% CI: 1.2-7.1) between seropositivity to HPV 16/18/33 VLPs and 
same-sex oral sexual intercourse among male participants of an oral HPV study [31]. 
History of having same-sex anal or oral sexual intercourse may serve as a surrogate 
marker for increased sexual exposure to the virus via multiple transmission routes 
including oral-penile, oral-anal and penile-anal transmission. With the absence of 
information on oral and anal HPV infection among this cohort of men, we could only 
hypothesize that an increased risk of oral or anal HPV infection in addition to genital 
infection may have contributed to increased seroconversion observed among MSM and 
MSMW. This hypothesis is also supported by findings from several recent studies. 
D’Souza et al. reported a higher prevalence of oral HPV infection with genital HPV types 
among MSM and MSMW compared to heterosexual men [26]. A high prevalence of anal 
HPV infection was reported among HIV-positive MSM from HIV/AIDS clinics in Montreal 
[50] as well as HIV-negative MSM in a community-based study [51]. Further studies of 
serum antibody development following incident HPV infection at different anatomic sites 
are needed to test this hypothesis.  
Results of the current study were inconclusive regarding whether HPV 16 or 18 
serum antibodies were effective in protecting against subsequent infection with the 
homologous or phylogenetically related HPV types. A protective role of serum antibodies 
to HPV 16 was shown by Ho and colleagues in a prospective study of 247 female 
college students [38]. Women with a high titer level of IgG antibodies (OD>400-800) to 
HPV 16 in 2 or more consecutive visits had a lower risk for subsequent infection with 
HPV 16 (RR=0.49; p=0.037) and with HPV 16-related types (p=0.010) [38]. In contrast, 
no protective effect was reported by Viscidi et al. in the natural history study of 7,046 
Guanacaste women for whom the risk of subsequent infection was measured at the 
follow-up visit scheduled 5-7 years after the baseline serology. It is likely that the 
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inconclusive results on protective effect of serum antibodies in this study compared with 
female studies are in part attributable to potential gender difference in viral shedding and 
antibody response as observed in several serology studies that enroll both men and 
women [31, 33-37], and further compounded by the relative small sample size in the this 
study. Therefore, caution should be taken in interpreting the inconclusive finding of this 
study in men.  
 The current study has a number of limitations. First, we only enrolled men aged 
18-44 years. The narrow age range prohibits an evaluation of age effect in older men. 
Another limitation of the current study is that we were not able to evaluate the risk of 
subsequent infection based on a quantitative measure of antibody titer. The percent of 
HPV-infected men who seroconvert remains unknown, as is the longevity of serum 
antibodies in men. Serum antibodies elicited by distant, past infection may wane over 
time like serum antibodies to other viral infections such as hepatitis B virus, leading to 
potential exposure misclassification. Additional limitations include the relatively small 
sample size and limited duration of follow-up which may have lowered statistical power 
needed to detect a statistically significant difference in the risk of type-specific or group-
specific infections given the low incidence for HPV types of interest. 
 In summary, the current study identified age, marital status, smoking status and 
sexual practice as factors significantly and independently associated with HPV 16/18 
serum antibody status. We did not detect statistically significant associations between 
the baseline serum antibody status and subsequent risk of infection. Large prospective 
studies that employ quantitative assessment of HPV antibody titers are needed to 
adequately address fundamental questions regarding the role of natural immunity in the 
natural history of HPV infections in men. 
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Table 2.1 Factors associated with HPV-16/18 seropositivity in 285 men in Tucson, 
Arizona 
 
Baseline Seroprevalence Crude  Adjusted § 
Characteristics 
No. Subjects 
(% Seropositive) OR 95% CI  OR 95% CI 
Age        
18-25 113 (13.3) 1.0   1.0  
26-35 86 (19.8) 1.3 (0.7-2.4)  0.6 (0.3-1.2)  
36-44 86 (58.1) 5.6 (3.4-9.3) * 4.2 (2.2-8.1) * 
Race       
White 237 (29.1) 1.0   --  
Non-white 38 (26.3) 0.7 (0.3-1.3)  --  
Marital Status       
Single/Never married 182 (23.6) 1.0   1.0  
Married/Cohabiting 69 (34.8) 1.6 (0.99-2.7)  1.5 (0.8-2.6)  
Divorced/Separated/Widow 34 (44.1) 3.2 (1.7-6.1) * 2.3 (1.02-5.3) * 
Education       
High school graduate or less 69 (26.1) 1.0   --  
Some college/vocational school  98 (24.5) 1.0 (0.6-1.8)  --  
College graduate/graduate school 118 (33.9) 1.2 (0.7-2.1)  --  
Cigarette smoking       
Never 95 (21.1) 1.0   1.0  
Former 54 (33.3) 2.2 (1.2-4.1) * 2.0 (1.03-3.9) * 
Current 67 (35.8) 1.8 (0.99-3.2)  1.5 (0.8-2.8)  
Alcohol use (drinks per month)       
0-13 66 (33.3) 1.0   --  
14-52 103 (29.1) 1.0 (0.7-1.3)  --  
≥ 53 56 (21.4) 0.8 (0.5-1.1)  --  
Circumcision (clinical assessment)      
No 35 (31.4) 1.0   --  
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Baseline Seroprevalence Crude  Adjusted § 
Characteristics 
No. Subjects 
(% Seropositive) OR 95% CI  OR 95% CI 
Yes 250 (28.4) 1.1 (0.6-2.0)  --  
Age at first sexual intercourse       
<18 160 (33.1) 1.4 (0.9-2.2)  --  
≥18 113 (23.9) 1.0   --  
Sexual practice       
Sexual intercourse with women 242 (26.4) 1.0   1.0  
Sexual intercourse with men 13 (46.2) 2.4 (0.9-6.2)  2.6 (1.05-6.7) * 
Sexual intercourse with both 13 (53.8) 2.9 (1.01-8.4) * 2.1 (0.7-5.8)  
Lifetime no. of sex partners (either sex)      
0-4 82 (19.5) 1.0   1.0  
5-16 130 (23.1) 1.1 (0.6-1.8)  0.6 (0.3-1.3) 
≥17 68 (51.5) 2.3 (1.3-4.1) * 1.0 (0.4-2.1) 
No. of new sex partners in the past 3 months       
None 160 (27.5) 1.0   --  
One or more 94 (29.8) 1.0 (0.7-1.3)  --  
Diagnosed with other STI since last visit **      
No 204 (26.5) 1.0   --  
Yes 75 (36.0) 1.5 (0.9-2.4)  --  
Had partner(s) with other STI since last visit **      
No 103 (18.4) 1.0   --  
Yes 124 (34.7) 1.1 (0.9-1.5)  --  
Condom use in the past 3 months       
Never 86 (30.2) 1.0   --  
Sometimes 41 (34.1) 1.0 (0.7-1.5)  --  
Frequently 40 (25.0) 0.8 (0.5-1.1)  --  
Always 45 (20.0) 1.1 (0.7-1.8)  --  
HPV 16/18 infection(s)       
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Baseline Seroprevalence Crude  Adjusted § 
Characteristics 
No. Subjects 
(% Seropositive) OR 95% CI  OR 95% CI 
No 270 (29.3) 1.0   --  
Yes 9 (22.2) 1.2 (0.6-2.4)  --  
Note. OR: Odds Ratio. 95% CI: 95 percent confidence interval.     * denotes statistical significance (α= 0.05)      
§ The final model included age, marital status, cigarette smoking, lifetime number of sexual partners and 
sexual practice. 
** Other STIs include genital warts, genital Herpes, Chlamydia, gonorrhea, syphilis, non-gonococcal 
urethritis, hepatitis B, hepatitis C and HIV. 
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Table 2.2 Risk of subsequent infection with type-specific and group-specific HPV by 
baseline serum antibody status. 
 
Baseline Serum 
Antibody Status 
HPV Type 
Acquired 
Subsequently 
No. of 
Persons
At Risk 
No. of 
Incident 
Cases 
Person-
months 
Incidence Rate 
(per 1000 
person-months) 
Incidence Rate 
Ratio 
(95% CI) 
Anti-HPV 16 antibody     
Seropositive HPV 16 41 3 536 5.6 1.1 (0.3-4.0)
Seronegative 235 15 3076 4.9 1.0
Seropositive HPV 16-related types * 39 2 515 3.9 0.6 (0.1-2.6)
Seronegative 231 19 2996 6.3 1.0
Seropositive Other HPV types 30 11 353 31.1 1.2 (0.6-2.4)
Seronegative 176 52 2073 25.1  1.0
Anti-HPV 18 antibody     
Seropositive HPV 18 60 1 809 1.2 1.8 (0.2-20.2)
Seronegative 223 2 2966 0.7  1.0
Seropositive HPV 18-related types ** 55 3 727 4.1  0.6 (0.2-2.0)
Seronegative 211 19 2776 6.8  1.0
Seropositive Other HPV types 41 15 465 32.3  1.3 (0.7-2.3)
Seronegative 168 49 1988 24.6  1.0
Note. 95% CI: 95 percent confidence interval. 
* HPV 16-related types include HPV 31, 33, 35, 52, 58 and 67. 
** HPV 18-related types include HPV 39, 45, 59, 68 and 70. 
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ABSTRACT 
Background. Few HPV serology studies have evaluated type-specific 
seroprevalence of all vaccine HPV types in men. The present study investigates 
seroprevalence of HPV 6, 11, 16 and 18, and associated risk factors in men residing in 
three countries (U.S., Mexico and Brazil). 
Methods. Data from 1477 men aged 18-70 enrolled in the HIM Study were 
analyzed. Serum antibody testing was performed with virus-like particle-based ELISA. 
Potential risk factors were assessed for individual HPV types using Logistic regression. 
Results. Overall, HPV-6, 11, 16 and 18 seroprevalence was 14.8%, 17.3%, 
11.2% and 5.8%, respectively. Thirty-four percent of men were seropositive to ≥1 HPV 
types. When examined by sexual practice, 31.2% of men who had sex with women 
(MSW), 65.6% of men who had sex with men (MSM) and 59.4% of men who had sex 
with both men and women (MSMW) were seropositive to ≥1 HPV types. Seroprevalence 
increased with age among young-to-middle-aged men with significant upward age trends 
observed for HPV 11, 16 and 18. Men with multiple lifetime male anal sex partners were 
2-4 times more likely to be HPV 6 or 11 seropositive, and 3-11 times more likely to be 
HPV 16 or 18 seropositive.  
Conclusion.  Our data indicate that exposure to vaccine HPV types was 
common in men, particularly among MSM and MSMW. The practice of same-sex anal 
sex appears to be the strongest determinant for seroprevalence of all vaccine HPV 
types. 
 
 
Key Words: Serum antibodies, seroprevalence, risk factors, Human Papillomavirus, 
Men who have sex with men, Men who have sex with men and women, same-sex 
sexual intercourse
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INTRODUCTION 
HPV infections cause approximately 85% of squamous cell anal cancer, 50% of 
penile cancer, 33-72% of oropharyngeal cancers, and 10% of laryngeal cancers [14, 49, 
52, 53]. High prevalence of genital HPV infection has been reported in recent studies 
[17-19] with 25.8-72.9% of HIV-negative adult men testing positive for genital HPV. Anal 
and oral HPV, though less common, is present in 8.0-16.6% [20-22], and 2.9-7.6% [23] 
of HIV-negative adult men, respectively. Compared to men who have sex with women 
(MSW), men who have sex with men (MSM) and men who have sex with men and 
women (MSMW) were several times more likely to be infected with genital, anal or oral 
HPV, and hence at increased risk for HPV-associated diseases and cancers [24-28, 54].  
Serum antibodies elicited by natural HPV infection reflect cumulative exposures 
to HPV over time and across anatomic sites. Anti-HPV serum antibody IgG detected by 
VLP-based assays are type-specific [49, 55, 56]. There is typically a 6-12 month latency 
for detection of antibodies following HPV DNA detection, as observed in women [57, 58]. 
Antibodies appear to be stable over time and remain detectable even after a decade [59-
62]. Not all individuals challenged by natural exposure to HPV develop antibody 
responses detectable by current serology assays. Approximately 30-40% of women with 
incident HPV 16 infection failed to demonstrate seropositivity months following DNA 
detection [57, 58]. Similar data in men are not yet available. Although issues like 
differential seroconversion rates following infection for different HPV types, and unknown 
longevity of serum antibodies, could limit faithful translation, HPV serology remains a 
useful means for estimating cumulative HPV exposures in a population. With the recent 
licensure of the quadrivalent HPV vaccine for use in males, information on 
seroprevalence of vaccine-type HPV in the general male population is needed to provide 
guidance for strategic planning of vaccination. To date, few studies have characterized 
seroprevalence of all HPV types targeted in current vaccines and investigated 
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associated risk factors in men [30, 31, 33-37, 63-65]. Using baseline data from a large 
natural history study of HPV, we determined the seroprevalence of HPV 6, 11, 16 and 
18, respectively, and identified demographic and behavioral factors that were 
independently associated with individual HPV seroprevalence in men. 
METHODS 
 Study Population.   The present study included a subset of participants enrolled 
in the HPV Infection in Men Study (the HIM Study), a multi-national longitudinal study of 
HPV infection in men. Details of the cohort have been reported elsewhere [66]. In brief, 
4074 healthy men were recruited in São Paulo, Brazil, Cuernavaca, Mexico, and Tampa, 
Florida, United States, between June 2005 and August 2009. Men were recruited from 
several population sources in Brazil including public health clinic attendees, partners of 
women participating in a natural history study of HPV, and the general population. In 
Mexico, men were recruited from employees and beneficiaries of a large government 
agency and military officials. In the U.S., men were recruited from the University of South 
Florida and the greater Tampa metropolitan area. Men were considered eligible if the 
following criteria were met: (a) 18–70 years of age; (b) residents of 3 study sites; (c) no 
prior diagnosis of penile or anal cancers; (d) no prior diagnosis of genital or anal warts; 
(e) no symptoms of a sexually transmitted infection (STI) or current treatment of an STI; 
(f) no concurrent participation in an HPV vaccine study; (g) no history of HIV or AIDS; (h) 
no history of imprisonment, homelessness or drug treatment during the past 6 months; 
and (i) willingness to comply with 10 scheduled visits every 6 months for 4 years with no 
plans to relocate in 4 years. The current analysis included 1477 men with available 
serology, genital HPV DNA results and survey information from the enrollment visit. 
 Study Protocol.   At the enrollment visit, an extensive sexual history and health 
questionnaire was administered using Computer-Assisted Self-Interviewing (CASI) 
system to solicit information on participant socio-demographic characteristics, sexual 
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history, condom use, alcohol and tobacco consumption, and history of abnormal pap 
smears in female partners. A 10ml venous blood was collected for serum antibody 
testing and participant external genitalia were sampled for HPV DNA testing.  
 HPV Serum Antibody Testing.   Serum antibodies to HPV types 6, 11, 16, and 
18 were measured using VLP-based enzyme-linked, immunosorbent assay (ELISA) [67]. 
HPV 6, 11 and 18 VLPs were produced in insect cells from recombinant baculoviruses 
expressing the L1 major capsid protein of individual HPV types [68], and HPV 16 VLPs 
were produced in mammalian cells from plasmids expressing the L1 and L2 capsid 
proteins [69]. Specimens were tested in duplicate on separate plates, with retesting of 
specimens showing results exceeding a preset, acceptable coefficient of variation (CV) 
of 25%. Seropositivity was defined as an optical density (OD) value greater than the 
mean OD value plus 5 standard deviations, estimated using serum samples from 
children, 1 to 10 years of age, after exclusion of outliers. Quality control of the serology 
assays was assured by inclusion of laboratory-prepared positive and negative controls in 
each run of the assay.  
 HPV DNA Sampling and Testing.   Three pre-wetted Dacron swabs were used 
to collect exfoliated skin cells from the penis and scrotum and later combined to form a 
single specimen. All specimens were stored at -70°C until PCR analyses and genotyping 
were conducted. DNA was extracted from exfoliated skin cell samples using the QIAamp 
DNA Mini Kit (QIAGEN, Valencia, CA) and tested for HPV DNA using polymerase chain 
reaction (PCR) for amplification of a fragment of the HPV L1 gene [70]. HPV genotyping 
was conducted using the Linear Array HPV Genotyping Protocol (Roche Diagnostics, 
Indianapolis, IN) to detect 37 genital HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 
45, 51-56, 58, 59, 61, 62, 64, 66-73, 81-84, IS39, and CP6108 [41].  
 Statistical Analysis.  Overall seroprevalence and seroprevalence by sexual 
practice, age, country of residence, lifetime number of female partners and male anal 
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sex partners were presented in Figure1. Chi-squared and Cochran-Armitage test were 
used to compare seroprevalence and test for trends across levels of categorical 
variables, respectively. Serum antibody titer levels among seropositive men, as 
measured by OD values, were summarized by median and Interquartile Range (IQR). 
OD values were compared across levels of individual factors using Wilcoxon Rank-sum 
and Kruskal-Wallis test for each HPV type. The association between potential risk 
factors and HPV 6, 11, 16 or 18 seroprevalence, treated as a dichotomous outcome, 
was evaluated on a type-specific basis using unconditional logistic regression and 
measured by Odds Ratio (OR) and its 95% confidence intervals (CI). Factors examined 
included (1) sociodemographic characteristics such as age, country of residence, race, 
ethnicity, marital status, and educational attainment; (2) lifestyle and behavioral factors 
including alcohol consumption, smoking, circumcision, age at first sexual intercourse, 
sexual practice, the number of recent and lifetime sex partners, frequency of sexual 
intercourse, condom use, and history of other STIs; and (3) corresponding HPV DNA 
status at the same visit. Variables that demonstrated statistical significance at 0.1 level 
in the simple regression models were included in the multivariable regression models. 
Likelihood ratio tests and backward selection procedures were applied for variable 
selection. Factors were retained in the multivariable models if p values of likelihood ratio 
test were ≤0.05. Potential pair-wise interactions were explored. Because of the 
exploratory nature of the present study, no adjustment for multiple testing was made. 
RESULTS 
Characteristics of the 1477 men included in the current analysis and the median 
and inter-quartile range (IQR) of OD values among men seropositive to HPV 6, 11, 16 
and 18 are summarized in Table 3.1. Of the 1477 men, 546 (37.0%) were residents of 
Tampa, US, 440 (29.8%) residents of São Paulo, Brazil and 491 (33.2%) residents of 
Cuernavaca, Mexico. These men were predominantly under 35 years of age (62.4%), 
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single (unmarried) or cohabiting (57.2%), had college or higher education (52.1%), and 
uncircumcised (58.3%). 1247 (84.4%) men were identified as MSW, 64 (4.3%) as MSM, 
64 (4.3%) as MSMW, and 76 (5.1%) as men who reported never having any type of sex, 
based on their responses to multiple survey questions concerning their recent and 
lifetime sexual behaviors (Table 3.1).  
Overall, HPV 6, 11, 16 and 18 seroprevalence was 14.8%, 17.3%, 11.2% and 
5.8%, respectively (Figure 3.1.A). A total of 499 (33.8%) men were seropositive to ≥1 
HPV type, and only 8 (0.5%) men were seropositive to all four HPV types. 
Seroprevalence of HPV 6/11 was 25.7% and seroprevalence of HPV 16/18 was 14.8% 
for the entire cohort.  
When examined by sexual practice, 31.2% of MSW, 65.6% of MSM, 59.4% of 
MSMW, and 29.0% of men who never had sex were seropositive to ≥1 HPV type; and 
0.2% of MSW, 6.3% of MSM, 1.6% of MSMW, and 0% of men who never had sex were 
seropositive to all four HPV types. Seroprevalence of HPV 6/11 was 23.5% for MSW, 
51.6% for MSM, 45.3% for MSMW, and 25.0% for men who reported never having sex; 
whereas seroprevalence of HPV 16/18 was 11.8% for MSW, 50.0% for MSM, 45.3% for 
MSMW, and 7.9% for men who never had sex (Figure 3.1.A).  
The seroprevalence of HPV 6, 11, 16 and 18 increased with age among young-
to-middle-aged men (Figure 3.1.B) with significant upward age trends observed for HPV 
11, 16 and 18 seroprevalence. HPV 6 and 11 seroprevalence peaked at age 35-44 and 
declined in older age, while HPV 16 seroprevalence plateaued after peaking at age 35-
44 and HPV 18 seroprevalence continued to rise in older men. Seroprevalence also 
varied significantly by country of residence (Figure 3.1.C). Brazilian men had the highest 
seroprevalence for all HPV types among the three countries, reaching 19.5%, 25.0%, 
16.1% and 10.5%, respectively. Type-specific seroprevalence did not differ significantly 
by the number of lifetime female sex partners among MSW (Figure 3.1.D). In contrast, 
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there was a statistically significant, strong positive trend of seroprevalence associated 
with the number of lifetime male anal sex partners for each HPV type (Figure 3.1.E).  
The median and inter-quartile range (IQR) of serum antibody levels among 
seropositive men, as measured by OD values, were 0.234 (IQR: 0.187-0.312) for HPV 6, 
0.244 (IQR: 0.188-0.355) for HPV 11, 0.190 (IQR: 0.121-0.427) for HPV 16, and 0.172 
(IQR: 0.128-0.295) for HPV 18 (Table 3.1). Serum antibody levels differed significantly 
by sexual practice for all HPV types, and by lifetime number of male anal sex partners 
for HPV 6, 11 and 16. In addition, HPV 6 antibody levels differed significantly by the 
number of recent new sex partners; HPV 16 antibody levels differed by age and lifetime 
number of female sex partners; and HPV 18 antibody levels differed by circumcision 
status.  
In univariate analyses, common risk factors for seroprevalence of all four HPV 
types were age, country of residence, sexual practice, the number of lifetime male anal 
sex partners, and recent new sex partners of either sex (Table 3.2). Additional factors 
significantly associated with seroprevalence in univariate analyses included education 
and cigarette smoking for HPV 6 seroprevalence; ethnicity, race, marital status, 
education, cigarette smoking, circumcision, age at first sex, the number of lifetime 
female sex partners among MSW, frequency of recent vaginal sex, and concurrent 
detection of HPV 11 DNA for HPV 11 seroprevalence; race, marital status, recent 
condom use in anal sex, and the history of other STIs for HPV 16 seroprevalence; and 
education, cigarette smoking, circumcision, and the history of other STIs for HPV 18 
seroprevalence. 
In multivariable analyses, the number of lifetime male anal sex partners was 
independently associated with seroprevalence of HPV 6, 11, 16 and 18, respectively 
(Table 3.3). Men with multiple lifetime male anal sex partners were more likely to be 
seropositive to HPV 6, 11, 16 or 18 [Adjusted Odds Ratio (AOR) for ≥11 partners: 4.34 
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(95% CI: 2.28-8.29) for HPV 6; 2.32 (95% CI: 1.12-4.84) for HPV 11; 7.74 (95% CI: 3.96-
15.12) for HPV 16; and 11.46 (95% CI: 5.40-24.34) for HPV 18]. Increasing age was 
significantly associated with higher seroprevalence of HPV 11, 16 and 18, with an AOR 
of 1.50-1.58 for HPV 11, 1.81-2.23 for HPV 16 and 1.62-3.21 for HPV 18. In addition, for 
HPV 6, men with college or higher education had a significantly lower seroprevalence 
[AOR: 0.59 (95% CI: 0.41-0.85)]. For HPV 11, men with a recent new sex partner were 
significantly more likely to test seropositive [AOR: 1.64 (95% CI: 1.17-2.30)], whereas 
college-educated [AOR: 0.61 (95% CI: 0.43-0.88)] and circumcised men [AOR: 0.67 
(95% CI: 0.48-0.94)] were less likely to test seropositive. For HPV 16, married men had 
significantly lower seroprevalence [AOR: 0.54 (95% CI: 0.33-0.90)]. For HPV 18, 
Brazilian residency was significantly associated with higher seroprevalence [AOR: 2.09 
(95% CI: 1.04-4.19)].  
DISCUSSION 
The present study characterized the seroprevalence of four HPV types targeted 
in the currently licensed HPV vaccines and determined factors associated with individual 
HPV seroprevalence in 1477 men residing in U.S., Mexico and Brazil. Our findings 
demonstrate that approximately a third of cohort participants have been exposed to ≥1 
vaccine HPV types, and the risk of exposure was twice as high among MSM and 
MSMW. Age was significantly associated with seroprevalence of all vaccine HPV types 
except for HPV 6, and anal sex with men was significantly associated with a higher risk 
of seropositivity to individual HPV types.  
Age has been consistently associated with HPV seroprevalence in previous 
serology studies in men using VLP-based ELISA [30, 31, 33-37, 63-65, 71]. The upward 
age trends associated with HPV 16 and 18 seroprevalences observed in the current 
study are consistent with those reported in population-based [65], community-based [63, 
71] or clinic-based studies [33, 35-37]. Only few studies have evaluated HPV 6 and/or 11 
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seroprevalence in men [30, 33, 64] and their findings on age have been mixed. The 
study of Hariri et al. showed a significant, increasing age trend for HPV 11 
seroprevalence for males 6 to 49 years old followed by an insignificant decline through 
age 59 in a population-based study of 3589 men [64], similar to the age pattern 
observed for HPV 11 seroprevalence in the current study. In the remaining two studies, 
HPV 6 seroprevalence was significantly associated with older age (>35: OR, 2.2; 95% 
CI: 1.0-4.8) in the study of Hagensee et al.  [30], whereas no age association with HPV 
6/11 seroprevalence was detected by Slavinsky et al. [33]. The age patterns observed in 
the current study as well as previous studies likely reflect complex changes in individual 
immune capacity and the balance between HPV acquisition and clearance over their 
lifespan. The lack of age association in the study of Slavinsky et al [33] may be 
explained by the exclusive enrollment of highly sexually active STI clinic attendees who 
had multiple sex partners and a history of STI in the past year. It was also suggested 
that concomitant infection with other sexually transmitted agents may facilitate 
persistence of HPV infection, eliciting a stronger immune response and longer-lasting 
immune memory [34, 36, 37] and resulting in less variation in seroprevalence across age 
groups.  
Our data demonstrated that seroprevalence of vaccine HPV types differed 
significantly between MSW, MSM and MSMW. To our knowledge, this study is the first 
to compare vaccine-type HPV seroprevalence between men with different sexual 
practices. Overall, MSM and MSMW exhibited approximately 2-6 times higher 
seroprevalence compared to MSW. No statistically significant trend or association of 
HPV seroprevalence with the number of lifetime female sex partners was observed 
among MSW for any vaccine HPV type examined. In contrast, seroprevalence increased 
significantly with increasing number of lifetime male anal sex partners for individual HPV 
types, and significant independent associations were detected for men reporting multiple 
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male anal sex partners. The higher seroprevalence associated with the practice of 
same-sex anal sex is consistent with previous findings [31, 34, 64, 65], and is likely 
explained by the increased risk of simultaneous HPV infections (oral, genital and anal) at 
multiple anatomic sites among MSM and MSMW. It probably also implies that HPV 
infection at keratinized epithelium is less likely to induce an immune response than 
infection of mucosal epithelium. In addition, it is noteworthy that seroprevalence of 
vaccine HPV types among men who reported never having any type of sex was 
comparable to that reported for MSW, except for HPV 16 seroprevalence which was 
much lower among those with no sex. It is possible that besides sexual intercourse, HPV 
transmission may have occurred through other forms of contact such as skin contact and 
use of sex toys, or through vertical transmission although less likely. 
In the current study, circumcision was independently associated with lower HPV 
11 seroprevalence but not with any other vaccine HPV types. A statistically significant 
association with circumcision was also observed in univariate analysis of HPV 18 
seroprevalence. However, it was not retained in multivariate analyses. An approximately 
30% reduction in acquisition and 30% increase in clearance of oncogenic HPV infection 
was demonstrated in recent randomized-controlled trials of circumcision [72, 73]. In 
addition, 2-3 times higher likelihood of clearance for both oncogenic and non-oncogenic 
HPV infections was shown in longitudinal epidemiological studies [40, 74]. It is possible 
that the lower incidence and shorter duration of HPV 11 infection due to circumcision 
may have contributed to the lower HPV 11 seroprevalence observed among circumcised 
men. 
It was noted that in the present study detection of anti-HPV serum antibodies 
was not significantly associated with simultaneous presence of HPV DNA for any 
vaccine-type HPV, indicating a possible lag time between HPV DNA detection and 
detection of serum antibodies, and the limited value of serum antibodies as a marker of 
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current infection, consistent with what has been reported previously [58, 60, 75]. Our 
data also demonstrated substantial gaps between HPV DNA prevalence and 
seroprevalence. The gap was most prominent for HPV 11 (seroprevalence: DNA 
prevalence ratio=11.6) and least prominent for HPV 16 (seroprevalence: DNA 
prevalence ratio=1.8). It was suggested that longer presence of HPV DNA is associated 
with higher likelihood of seroconversion [57, 60]. With a longer duration of infection for 
HPV 16 than HPV 11 in this cohort of men [54], a smaller gap between HPV 16 DNA 
prevalence and seroprevalence was counterintuitive. However, HPV 16 and other 
oncogenic HPV were shown to have evolved an immune evasion mechanism inhibiting 
host detection of virus [76].  It was likely that the lack of immune evasion mechanism for 
HPV 11 and frequent presence of HPV 11-positive warts may have contributed to a 
higher seroconversion rate for HPV 11 than HPV 16. In addition, HPV 11 seroprevalence 
was associated with the presence of new sex partner in past 6 months, which may 
indicate a shorter latency period for HPV 11 serum antibody detection. The combination 
of a shorter latency and a higher seroconversion may have led to the great discrepancy 
observed between HPV 11 DNA prevalence and seroprevalence. Unique to HPV 6 and 
11, a higher level of education was significantly associated with lower seroprevalence, 
which was also observed in the study of Hariri et al [64]. We hypothesize that education 
is likely a marker of lifestyle characteristics which may impact potential HPV 
transmission.  
The major strengths of this study are the inclusion of men of a wide age range 
(18-70), especially those 60 and older, the age group that was rarely evaluated in 
previous studies; and the availability of detailed and extensive participant sexual 
behavioral information that has been previously validated [77]. However, several 
limitations must be addressed. First, this study is a cross-sectional analysis utilizing 
serology measured at the baseline of a large natural history study in men. With our 
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limited understanding of seroconversion rates following natural infection and the 
longevity of type-specific serum antibodies, baseline serostatus may underestimate the 
true proportion of cumulative HPV exposure, thus making it less informative for 
estimating population exposure. Second, differences in serological assays used, and the 
choice of control population and cutoff points for determining seropositivity between the 
present study and the previous studies may limit a direct comparison of seroprevalence 
in our study with those published previously. Finally, because of the recruitment method 
used in the present study, the cohort presented may not be a representative sample of 
the general male population of the participating country, which limits the generalizability 
of our findings.  
Despite the aforementioned limitations, the present study provided important 
data on the distribution of vaccine-type HPV exposure in community-based male 
populations from three countries, and epidemiological factors associated with 
seroprevalence of individual HPV types targeted in the current vaccines. Our results 
indicated exposure to vaccine HPV types is common in men and increased from young 
to middle-aged men. Our data also demonstrated that MSM and MSMW had greatly 
elevated risk of exposure to vaccine HPV types compared to MSW, and the engagement 
in same-sex anal sex was a significant determinant of seroprevalence for all vaccine 
HPV types. 
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A. Seroprevalence overall and by sexual practice. 
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B. Seroprevalence by age.         C. Seroprevalence by country of residence. 
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D.  Seroprevalence by lifetime female partners.  E. Seroprevalence by lifetime male anal sex partners. 
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Figure 3.1 Seroprevalences of HPV 6, 11, 16 and 18 overall and by sexual practice, age, 
country, and lifetime number of female and male sex partners. (A) Seroprevalence 
overall and by sexual practice; (B) Seroprevalence by age; (C) Seroprevalence by 
country of residence; (D) Seroprevalence by lifetime number of female sex partners 
among men who have sex with women (MSW); (E) Seroprevalence by lifetime number 
of male anal sex partners.
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INTRODUCTION 
Genital HPV infection is one of the most common sexually transmitted infections 
(STIs) in the United States [1]. Prevalence of up to 63% has been documented in U.S. 
men [17], with HPV 16 being the most frequently detected oncogenic HPV type [78, 79]. 
In women detectable anti-HPV 16 serum antibodies protect against subsequent genital 
HPV 16 infection and HPV 16-related CIN2+ in a population-based prospective study 
[80]. Whether a man’s risk of acquiring genital HPV 16 infection is altered by the 
presence of anti-HPV 16 serum antibodies remains unclear. We have previously 
reported that the detection of HPV 16 seropositivity was not associated with risk of 
subsequent genital HPV 16 infection among a cohort of U.S. men [71]. However, that 
study had a limited duration of follow-up and a relatively small sample size. In addition, 
unavailability of quantitative measurement of serum antibody titers had limited our ability 
to assess potential associations between circulating serum antibody titers and the risk of 
infection. 
Risk of HPV infection at different anatomic sites appear to differ between men 
who had sex with women (MSW), men who had sex with men (MSM) and men who had 
sex with both men and women (MSMW), with MSM and MSMW at increased risk of 
infection [26, 81]. There is also growing evidence that HPV infection acquired at various 
anatomic sites may differentially contribute to circulating antibody levels observed in 
men [31, 34, 64, 65, 82]. In previous HPV serology studies, men who had same-sex 
sexual intercourse were more likely to have detectable antibodies to HPV types 6, 11, 
16, or 18, compared to men who had sex with only women [31, 34, 64, 65, 82]. As a 
result, any potential protection conferred by detectable serum antibodies may differ 
between men with different sexual practices. In the current study we examined the risk 
of genital HPV 16 infection by enrollment serum antibody status in a large cohort of men, 
for the entire cohort and according to their sexual practices.  
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METHODS 
Study Population.   A multi-national longitudinal study of HPV infection in men 
(HIM Study) was conducted in Tampa, Florida, United States, São Paulo, Brazil, and 
Cuernavaca, Mexico.  Enrollment to the cohort occurred between June 2005 and August 
2009. Details of the cohort have been reported previously [66]. In brief, healthy men 
were recruited from several population sources in each study site and followed every six 
months for a maximum of 4 years. Men were eligible to participate if the following criteria 
were met: (a) 18–70 years of age; (b) residents of 3 study sites; (c) no prior diagnosis of 
penile or anal cancers; (d) no prior diagnosis of genital or anal warts; (e) no symptoms or 
current treatment for an STI; (f) no concurrent participation in an HPV vaccine study; (g) 
no history of HIV or AIDS; (h) no history of imprisonment, homelessness or drug 
treatment during the past 6 months; and (i) willingness to comply with 10 scheduled 
visits every 6 months for 4 years with no plans to relocate in 4 years. All eligible men 
signed an informed consent prior to enrollment. At the enrollment visit and each follow-
up visit, an extensive sexual history and health questionnaire was administered using 
Computer-Assisted Self-Interviewing (CASI) system. 10ml venous blood was collected 
for serum antibody testing and the external genitalia were sampled for HPV testing. The 
informed consent and the study protocol were reviewed and approved by appropriate 
internal review boards and human subject committees at each study site.   
A total of 4074 men residing in Tampa, São Paulo and Cuernavaca were enrolled 
in the HIM Study. The present analysis included a subset of 2187 men for whom HPV 16 
serology and survey information was available from the baseline, and HPV 16 DNA 
results available from the baseline and at least one follow-up visit as of August 31st, 
2010, and who tested negative for HPV 16 DNA at baseline. Comparison of participant 
characteristics indicated that the subset is comparable with the full study cohort of the 
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HIM Study with respect to socio-demographic characteristics, sexual behaviors and 
lifestyle factors, except that a slightly larger proportion of Brazilian participants were 
represented in the current cohort (Table 4.1). 
HPV Serum Antibody Testing.   Serum antibodies to HPV types 16 were 
measured using virus-like particle (VLP)-based enzyme-linked, immunosorbent assay 
(ELISA) [67]. HPV 16 VLPs were produced in insect cells from recombinant 
baculoviruses expressing HPV 16 L1 capsid proteins [68].  Specimens were tested in 
duplicate on separate plates, with retesting of specimens showing results exceeding a 
preset, acceptable coefficient of variation (CV) of 25%. Seroreactivity was measured by 
absorbance values, optical density (OD). The mean and standard deviation (SD) of 
absorbance values were estimated based on seroreactivity of serum samples from 
children, 1 to 10 years of age. The mean value plus 5 standard deviations was used as 
the cut point for seropositivity. Quality control of the serology assays was assured by 
inclusion of laboratory-prepared positive and negative controls in each run of the assay.  
 HPV DNA Sampling and Testing.   Three pre-wetted Dacron swabs were used 
to collect exfoliated skin cells from the penis and scrotum and later combined to form a 
single specimen. All specimens were stored at -70°C until PCR analyses and genotyping 
were conducted. DNA was extracted from exfoliated skin cell samples using the QIAamp 
DNA Mini Kit (QIAGEN, Valencia, CA) and tested for HPV DNA using polymerase chain 
reaction (PCR) for amplification of a fragment of the HPV L1 gene [83]. HPV genotyping 
was conducted using the Linear Array HPV Genotyping Protocol (Roche Diagnostics, 
Indianapolis, IN) to detect 37 genital HPV types [41]. Human β-globin was tested to 
assure the integrity of DNA and was detected in 94.9% (2076/2187) of baseline HPV 
samples tested. 
 Statistical Analysis. Participants were classified as MSW (89.3%), MSM (5.0%), 
and MSMW (5.7%) based on their responses to multiple survey questions regarding 
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their recent and lifetime sexual behavior. As the number of MSM and MSMW was small, 
and both groups of men engaged in same-sex sexual behaviors, MSM and MSMW were 
combined and regrouped as MSM in the current analysis. Characteristics of 
seronegative and seropositive men were compared using Chi-squared and Fisher’s 
Exact Test among the overall cohort, MSW and MSM, respectively. Two virological 
endpoints were evaluated: incidence of HPV 16 infection and incidence of 6-month 
persistent HPV 16 infection. An incident HPV 16 infection was defined as the first 
detection of HPV 16 DNA by the Linear Array assay during the follow-up period, 
assuming the date of detection as the date of occurrence. An incident 6-month persistent 
HPV 16 infection was defined as the detection of HPV 16 DNA at two or more 
consecutive visits during the follow-up period, using the date of first positive DNA 
detection as the date of occurrence. Incidence proportion of both endpoints for each 
study interval was summarized using the number of incident cases detected at the 
stated visit as the numerator and the number of participants who tested HPV 16 DNA 
negative at the prior visit and returned for the stated visit as the denominator. Cox 
proportional hazard regression was applied to compare risk of HPV 16 infection by 
participant baseline serostatus for the entire cohort, MSW and MSM, respectively, 
controlling for potential confounders. Serostatus was included in the Cox models as a 
binary variable (seropositive vs. seronegative) as well as a continuous variable 
measuring antibody titers, indicated by OD and log-transformed. Men who tested 
negative for HPV 16 DNA throughout their last available follow-up visit were considered 
censored at the last visit. Potential confounders considered included (1) socio-
demographic characteristics such as age, country of residence, race, ethnicity, marital 
status, and educational attainment; and (2) lifestyle and behavioral factors including 
alcohol consumption, smoking, circumcision, age at first sexual intercourse, sexual 
practice, the number of recent and lifetime sex partners, frequency of sexual intercourse, 
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condom use, and history of other STIs. Individual factor that demonstrated statistical 
significance at 0.1 level along with serostatus in Cox models was considered for 
inclusion in the multivariable models. Partial likelihood ratio and Wald tests were used 
for covariate selection using a backward elimination procedure. Hazard Ratio (HR) and 
its 95% confidence intervals (CI) were estimated from Cox regression models. All 2187 
men were included in the analysis of incident HPV 16 infection. Of the 2187 men, 1834 
men with DNA results for at least two consecutive follow-up visits remained in the 
analysis for incident 6-month persistent HPV 16 infection. 
RESULTS 
The cohort of 2187 men contributed a total of 10086 visits, equivalent to 4424 
person-years. 739 (33.8%) men were followed for approximately 12 months (2 follow-up 
visits), 728 (33.3%) for 24 months (4 visits), 559 (25.6%) for 36 months (6 visits), and 
161 (7.4%) for 48 months (8 visits). The mean and median duration of follow-up was 2.0 
years (range: 0.4-4.1; inter-quartile range: 1.2-3.0). The median interval between visits 
was 6.2 months.  
Characteristics of seronegative men and seropositive men were summarized in 
Table 4.2. Baseline seroprevalence of HPV 16 was 12.3% overall, 10.0% among MSW 
and 31.2% among MSM. Overall, seronegative and seropositive men differed 
significantly by age at enrollment, country of residence, the number of lifetime sex 
partners (either sex) and new sex partners (either sex) in the past 6 months. 
Seropositive men were more likely to be 25 years or older, Brazilian, and have a large 
number of lifetime sex partners and one or more new sex partners in past 6 months. 
Similarly, significant differences were observed in age at enrollment, country of 
residence, and the number of lifetime sex partners (either sex) and lifetime female sex 
partners between seronegative and seropositive MSW. Among MSM, seropositive men 
were significantly older compared to seronegative men at enrollment.  
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Overall, a total of 221 (10.1%) men developed incident HPV 16 infections 
(seronegative 9.8% vs. seropositive 12.6%), and 72 (3.9%) men developed 6-month 
persistent HPV 16 infections (seronegative 3.9% vs. seropositive 3.8%) during the study 
period (Table 4.3). A smaller proportion of seropositive men had incident HPV 16 
infections than seronegative men during the first year of follow-up (6 months: Overall 3.0 
vs. 3.3%; MSW 3.1 vs. 3.2%; MSM 2.7 vs. 5.0%; 12 months: Overall 2.1 vs. 3.0%; MSW 
1.8 vs. 2.8%; MSM 3.0 vs. 5.5%).  The difference was more apparent among MSM.  
However, the reduction in HPV 16 incidence was not sustained through out the study 
period.  Likewise, seropositive MSM had a lower incidence of 6-month persistent HPV 
16 infection than seronegative MSM (6 months: 0 vs. 2.1%; 12 months: 1.5 vs. 2.8%) in 
the first year which was not retained for the remaining study period.  
The risk of incident HPV 16 infection and 6-month persistent infection according 
to baseline serostatus were presented in Table 3. Overall, baseline serostatus was not 
associated with risk of incident HPV 16 infection in either univariate or multivariable 
analyses (HR: 1.23, 95% CI: 0.85-1.77; Adjusted HR: 1.22, 95% CI: 0.83-1.79) (Table 
4.4.a). Likewise, incidence of 6-month persistent HPV 16 infection was not associated 
with baseline seropositivity in either univariate (HR: 0.96, 95% CI: 0.48-1.93) or 
multivariable analysis (Adjusted HR: 1.05, 95% CI: 0.51-2.16) (Table 4.4.b).  
When we examined the same associations according to sexual practices, the risk 
of incident HPV 16 infection was not associated with baseline serostatus among MSM 
(Adjusted HR: 1.23, 95% CI: 0.60-2.50) or MSW (Adjusted HR: 1.60, 95% CI: 0.98-2.60) 
(Table 4.5.a). Insignificant associations were also detected in the analysis of 6-month 
persistent HPV 16 infection among MSM and MSW, respectively (Table 4.5.b). An 
insignificant negative association between baseline seropositivity and risk of 6-month 
persistent HPV 16 infection was observed among MSM in the univariate analysis (HR: 
0.53, 95% CI: 0.11-2.51). However, the association was not confirmed in the 
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multivariable analysis (Adjusted HR: 1.03, 95% CI: 0.21-4.98). No protection against 6-
month persistent HPV 16 infection was observed among MSW. 
We further determined if higher serum antibody titers were associated with lower 
likelihood of subsequent HPV 16 infection. We did not observed significant associations 
between serum antibody titers and risk of incident HPV 16 infection and 6-month 
persistent HPV 16 infection for the overall cohort, MSW or MSM, respectively (Table 
4.6.a-b). Nor did we observe significant associations after we further restricted the 
analysis to seropositive men only (data not shown). 
DISCUSSION 
In this multi-national prospective study of healthy men, we assessed the risk of 
genital HPV 16 infection over a 48-month study period by baseline HPV 16 serostatus to 
determine if anti-HPV 16 serum antibodies induced by prior infection confer protection 
against subsequent acquisition of HPV 16 infection. Our study is one of the few studies 
that investigate the potential protective role of serum antibodies in the natural history of 
genital HPV in men. Two endpoints were evaluated, respectively: incident HPV 16 
infection and 6-month persistent HPV 16 infection. Overall the risk of incident HPV 16 
infection appeared to be lower in seropositive men compared to seronegative men within 
the first year of study period, particularly among MSM. Likewise, MSM had a lower 
incidence of 6-month persistent infection within the first year. However, no statistically 
significant associations between baseline HPV 16 seropositivity and risk of incident HPV 
16 infection or 6-month persistent HPV 16 infection over the entire study period were 
detected. Nor did we find that higher HPV 16 serum antibody titers were significantly 
associated with lower risk of infection.  
While we were not able to demonstrate statistically significant differences in the 
risk of HPV 16 infection, our data showed that HPV 16 incidence was lower among 
seropositive men compared to seronegative men during the first year of follow-up, 
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became higher and remained higher among seropositive men in the months that follow. 
Previous studies in women have shown that in the absence of viral antigen, serum IgG 
antibody titers attenuate over time. In the prospective study of Shoultz et al [84], female 
STI clinic attendees were followed every 4 month for a median of 24.6 month for 
repeated assessment of serostatus using L1 VLP-based capture ELISA. Among 197 
women with at least two consecutive HPV 16 seropositives during the study period, the 
median antibody titer was observed to decline by nearly 30-35% within 12-18 months 
following initial detection and to remain relatively stable over a long period of follow-up. 
Whereas, among 223 women who tested HPV 16 seropositive only once, the median 
antibody titer declined by approximately 70% in the first 6 months, remained below the 
positive cut-point for the remainder of the year, and rebound and fluctuated around 
positive cut-point throughout the study period [84]. Similarly, Ho et al reported 
cumulative probabilities of losing anti-HPV 16 IgG seropositivity by 12, 24 and 36 
months were 38.5%, 40.0% and 48.2% among female university students who tested 
seropositive at least once during the study period by L1/ L2 VLP-based direct ELISA 
[58]. The loss of serum antibody titer over time is a possible explanation for our findings. 
This hypothesis needs to be tested in future studies where repeated assessments of 
serum antibody and DNA status are available. 
Both the risk of incident HPV 16 infection and 6-month persistent HPV 16 
infection was observed to be insignificantly associated with baseline HPV 16 serostatus 
or serum antibody titers in our cohort, which is consistent with what we found previously 
in men [71]. Findings from serology studies in women have been mixed [38, 39, 80, 85, 
86]. Using L1/L2 VLP-based direct ELISA, Ho et al demonstrated that persistence of 
high anti-HPV 16 antibody titers at ≥2 consecutive visits was associated with lower risk 
of subsequent HPV 16 infection (Adjusted RR: 0.49; p=0.037) among female university 
students [38]. Wentzensen et al. showed a significant reduction in the risk of subsequent 
 - 50 -
HPV 16 infection or HPV 16-positive CIN2+ for seropositive women compared to 
seronegative women using a VLP-based ELISA (Adjusted OR: 0.60, 95% CI: 0.40-0.90) 
and a competitive Luminex-based immunoassay (cLIA) (Adjusted OR: 0.44, 95% CI: 
0.21-0.93) in a nested case-control study of 974 participants of the Guanacaste Natural 
History Study [80]. In addition, a protective effect was observed by Velicer et al among 
women aged 24-34 enrolled in the placebo arm of a HPV vaccine trial using cLIA, as 
evidenced  by a lower incidence of HPV 6/11/16/18 infection and 6-month persistent 
infection among baseline seropositive women compared to seronegative women 
(incident infection: 1.0 [0.31–2.23] vs. 5.7 [4.68–6.84] per 100 woman-years; 6-month 
persistent infection: 0.4 [0.05–1.37] vs. 2.5 [1.89–3.35] per 100 woman-years) [86]. In 
contrast, no protective effect was reported by Viscidi et al among 7,046 women enrolled 
in the Guanacaste cohort (RR: 0.74, 95% CI: 0.45–1.20) [39], or by Trottier et al among 
1,902 women enrolled in the Ludwig-McGill cohort both using a L1/L2 VLP-based direct 
ELISA assay (Incidence: Lowest tertile of antibody titers 1.6 [95% CI: 1.3–2.1] vs. 
Highest tertile 2.1 [95% CI: 1.7–2.6] per 1000 woman-months) [85]. 
The lack of protection observed in the present study in contrast to the relatively 
strong protection observed in female studies could be due to several factors, including 
differential gender-related immune response, assay differences and varying persistence 
of serum antibodies. Gender differences in seroprevalence have been reported in 
multiple studies [29, 31, 34, 36, 37, 65]. Seroprevalence of oncogenic and non-
oncogenic HPV was consistently higher among women than men from the same source 
population. The observed gender-specific immune response probably implies that HPV 
infection at keratinized epithelium is less likely to induce an immune response than 
infection of mucosal epithelium. Furthermore, differences in serological assays used 
across studies may explain the inconsistent results across publications. The VLP-based 
direct-binding ELISA assay used in the current study measures total type-specific 
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binding IgG antibodies, including neutralizing and non-neutralizing antibodies; whereas 
the competitive neutralization assay utilized by Wentzensen et al [80] and Velicer et al 
[86] measures IgG antibodies that bind to known neutralizing epitopes in HPV viral 
capsid. The inclusion of non-neutralizing antibodies in the present study could have led 
to overestimation of neutralizing antibody titers, and biased the association of protection 
toward null. Lastly, persistence of serum antibodies could have played a role in 
conferring protection. A protective effect of serum antibodies against incident infection 
with HPV 16 and its related types was observed among young women who had high 
antibody titer detected at ≥2 consecutive visits using a direct ELISA assay in the study of 
Ho et al [38]. In contrast, no protection was detected in other studies in women that 
measured serostatus only once at the baseline using similar assay [39, 86].  
Among all incident HPV 16 infections that occurred over the study period, ~35% 
of cases in the seronegative group and ~24% of cases in the seropositive group were 
detected at the 6-month visit. It was unclear what proportion of these infections may in 
fact be reactivation of prior infections. In an attempt to distinguish the possible 
reactivated infection from the truly new infection, we evaluated the risk of incident and 6-
month persistent infection with HPV 16 by baseline serostatus after restricting incident 
cases to those detected at the 12-month visit or later (Table 4.7.a-b). However, no 
significant association between baseline serostatus and risk of infection was observed in 
the restricted analysis. 
The present study is unique in its longitudinal design, the size of the cohort, the 
long duration of follow-up achieved in a large proportion of the cohort, and the availability 
of repeated measurements of HPV 16 DNA status. Yet limitations of the study have to 
be addressed. As the serum antibody measurement was only obtained once at 
enrollment, with natural fluctuation or attenuation of serum antibody titer over time [45, 
58], there was possible misclassification of baseline serostatus which could have driven 
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the association toward the null. Finally, despite the relatively large sample size for the 
present analysis, due to the low incidence of HPV 16 and the small proportion of MSM, 
our stratified analyses remained statistically underpowered to detect potential significant 
associations of HPV 16 acquisition with baseline serostatus among MSM.  
In conclusion, our data indicated that the presence of anti-HPV 16 serum 
antibodies at baseline did not alter the risk of HPV 16 acquisition in men. Future studies 
that investigate the effect of serum antibodies on the acquisition and clearance of HPV 
infection taking into account the duration of serum antibody presence are necessary to 
provide a greater understanding of the role of serum antibodies in the natural history of 
HPV in men. 
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Table 4.1 Participant characteristics in the current cohort and in the full study cohort of 
the HIM Study. 
Current Cohort 
(N=2187) 
 Full HIM Cohort 
(N=4074) Characteristics 
n (%)  n (%) 
p values† 
Age, years   0.513 
18-24  643 (29.4) 1232 (30.2)  
25-44 1240 (56.7) 2315 (56.8)  
45-70  304 (13.9)  527 (12.9)  
Country   0.003 
Brazil  819 (37.4) 1401 (34.4)  
Mexico  735 (33.6) 1330 (32.6)  
US  633 (28.9) 1343 (33.0)  
Marital   0.719 
Single  975 (44.7) 1838 (45.2)  
Cohabiting  280 (12.8)  484 (11.9)  
Married  744 (34.1) 1384 (34.1)  
Divorced/Widowed  183 ( 8.4)  357 ( 8.8)  
Education   0.717 
Less than high school  464 (21.3)  900 (22.2)  
High School graduate  593 (27.2) 1089 (26.8)  
College or higher 1124 (51.5) 2071 (51.0)  
Alcohol drinking a   0.722 
Light  692 (43.2) 1281 (43.9)  
Moderate  574 (35.8) 1012 (34.6)  
Heavy  336 (21.0)  628 (21.5)  
Cigarette smoking   0.462 
Never  455 (33.3)  845 (33.0)  
Current  489 (35.8)  963 (37.6)  
Former  422 (30.9)  751 (29.3)  
Circumcision b   0.070 
No 1437 (65.7) 2583 (63.4)  
Yes  750 (34.3) 1491 (36.6)  
Sexual practice   0.798 
MSW 1953 (89.3) 3429 (89.7)  
MSM  109 ( 5.0)  176 ( 4.6)  
MSMW  125 ( 5.7)  217 ( 5.7)  
Lifetime female sex partners among MSW, no.  0.597  
None  2 ( 0.1)  3 ( 0.1)  
1-3  510 (27.8)  835 (26.1)  
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Current Cohort 
(N=2187) 
 Full HIM Cohort 
(N=4074) Characteristics 
n (%)  n (%) 
p values† 
4-17  876 (47.8) 1574 (49.1)  
>=18  446 (24.3)  792 (24.7)  
Lifetime male anal sex partners, no.  0.366  
None 1829 (85.1) 3480 (86.6)  
1-2  149 ( 6.9)  238 ( 5.9)  
3-10 96 ( 4.5)  168 ( 4.2)  
>=11 76 ( 3.5)  132 ( 3.3)  
New sex partners in past 6 mo, no.  0.445  
None 1335 (61.4) 2530 (62.4)  
1  555 (25.5)  976 (24.1)  
≥2  285 (13.1)  548 (13.5)  
Frequency of vaginal sex in past 6 mos.  0.625  
<1 per week  724 (46.6) 1339 (48.1)  
1-2 per week  402 (25.9)  712 (25.6)  
>2 per week  427 (27.5)  735 (26.4)  
Condom use in vaginal sex in past 6 mos.   0.312  
Always  447 (23.9)  723 (22.0)  
Frequently  433 (23.2)  749 (22.8)  
Sometimes  256 (13.7)  490 (14.9)  
Never  732 (39.2) 1323 (40.3)  
Condom use in anal sex in past 6 mos.  0.884  
Always  235 (33.7)  391 (32.0)  
Frequently  121 (17.3)  211 (17.3)  
Sometimes 69 ( 9.9)  122 (10.0)  
Never  273 (39.1)  497 (40.7)  
Condom use in sexual intercourse in past 6 mos.  0.425  
Always  376 (22.9)  644 (21.1)  
Frequently  362 (22.1)  657 (21.5)  
Sometimes  195 (11.9)  385 (12.6)  
Never  708 (43.1) 1364 (44.7)  
History of other STIs c   0.367 
No 1783 (81.6) 3356 (82.5)   
Yes  402 (18.4)  711 (17.5)  
† p values were derived from Pearson chi-squared test statistics. Bolded p values denote statistical significance. 
a. Light drinking was defined as <half a drink per day; moderate drinking as one half to 2 drinks per day; and heavy 
drinking as >2 drinks per day on average. 
b. Circumcision status was assessed by study clinician. 
c. Other STIs: Chlamydia, HSV, genital warts, Gonorrhea, Hepatitis B, Hepatitis C, non-gonococcal urethratitis, Syphilis
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Table 4.3 Incidence proportion of HPV 16 infection and 6-month persistent infection by 
study visit and baseline serostatus 
A. Incident HPV 16 Infection 
    Incident HPV 16 Infection  
 Visit 6 months 12 months 18 months 24 months 30 month 36 months
no. infections (%†) n (%) n (%) n (%) n (%) n (%) n (%)
Total
Overall Seronegative        64 (3.3)         48 (3.0)         34 (2.7)       22 (2.4)      10 (1.6)         9 (2.2) 187
 Seropositive          8 (3.0)         5 (2.1)          7 (3.8)         6 (4.3)         3 (2.9)         5 (6.7) 34
MSW Seronegative         56 (3.2)         40 (2.8)         31 (2.7)       19 (2.3)         7 (1.2)          7 (1.9) 160
 Seropositive          6 (3.1)          3 (1.8)          6 (4.5)         2 (2.0)         1 (1.4)          4 (8.0) 22
MSM Seronegative          8 (5.0)          8 (5.5)          3 (2.7)         3 (3.5)         3 (5.1)          2 (4.9) 27
 Seropositive          2 (2.7)          2 (3.0)          1 (2.0)      4 (10.5)        2 (6.7)          1 (4.0) 12
 
B. 6-month Persistent HPV 16 Infection     
  6-month Persistent HPV 16 Infection 
 Visit 6 months 12 months 18 months 24 months 30 month 
no. infections (%†) n (%) n (%) n (%) n (%) n (%) Total 
Overall Seronegative         20 (1.3)         18 (1.1)         14 (1.1)         6 (0.7)         5 (0.8) 63 
 Seropositive          3 (1.3)          3 (1.3)         2 (1.1) 0 (0)         1 (1.0) 9 
MSW Seronegative         17 (1.2)         14 (1.0)         14 (1.2)         5 (0.6)         5 (0.9) 55 
 Seropositive          3 (1.8)          2 (1.2)          1 (0.8) 0 (0)         1 (1.4) 7 
MSM Seronegative          3 (2.1)          4 (2.8) 0 (0)         1 (1.2) 0 (0) 8 
  Seropositive 0 (0)          1 (1.5)          1 (2.0) 0 (0) 0 (0) 2 
† % represents the percent of all participants at risk (men who were HPV negative at the prior visit and 
followed until the stated visit or later). 
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Table 4.4 Association of incident HPV 16 infection and 6-month persistent HPV 16 
infection with baseline serostatus (seronegative vs. seropositive) among 2187 
men in Tampa, Cuernavaca and São Paulo. 
A. Incident HPV 16 infection 
  Incident HPV 16 Infection (N=2187) 
 
no.  
subjects 
no.  
infections
HR 95% CI 
Adjusted 
HR† 
95% CI 
HPV 16 Serostatus      
Negative 1918 187 1.00  1.00  
Positive 269 34 1.23 (0.85-1.77) 1.22 (0.83-1.79) 
HR: Hazard Ratio.   CI: Confidence interval. 
†. Adjusted for age at enrollment, sexual practice (MSW and MSM) and lifetime number of sex partners. 
 
B. 6-month persistent HPV 16 infection 
    6-month Persistent Infection (N=1834) 
   
no.  
subjects 
no.  
infections
HR 95% CI 
Adjusted 
HR† 
95% CI 
HPV 16 Serostatus      
Negative  1598 63 1.00  1.00  
Positive   236 9 0.96 (0.48-1.93) 1.05 (0.51-2.16) 
HR: Hazard Ratio.   CI: Confidence interval. 
†. Adjusted for age at enrollment, sexual practice (MSW and MSM) and the number of new sex partners in past 6 months. 
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Table 4.7 Association of incident HPV 16 infection and 6-month persistent HPV 16 
infection with baseline serostatus (seronegative vs. seropositive) in the restricted 
analysis 
 
A. Incident HPV 16 infection 
  Incident HPV 16 Infection 
Overall (N=1770)  MSW (N=1568)  MSM (N=202) 
 
HR 95% CI   HR 95% CI   HR 95% CI 
HPV 16 Serostatus               
Negative 1.00   1.00   1.00  
Positive 1.41 (0.92-2.15)   1.31 (0.77-2.22)   1.06 (0.49-2.29) 
 
B. 6-month persistent HPV 16 infection 
  6-month Persistent HPV 16 Infection 
Overall (N=1811)  MSW (N=1603)  MSM (N=208) 
  
HR 95% CI   HR 95% CI   HR 95% CI 
HPV 16 Serostatus               
Negative 1.00   1.00   1.00  
Positive 0.93 (0.40-2.19)   0.90 (0.32-2.52)   0.85 (0.16-4.36) 
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CHAPTER 5: 
 
CONCLUSIONS AND RECOMMENDATIONS 
Data from our studies indicate that exposure to HPV 6, 11, 16 and 18, the four 
HPV types targeted in the currently license HPV vaccines, is common. Of 285 male 
residents of Tucson, Arizona, 28.8% of them were seropositive to HPV 16 and/or 18 at 
study entry. Similarly, approximately one third of 1477 participants of the multi-national 
male HPV natural history study were seropositive to at least one vaccine HPV type, with 
the percentage of 21.8% in U.S. site, 33.4% in Mexico site, and 49.1% in Brazil site. It is 
also noted that seroprevalence of individual vaccine HPV types is greatly elevated 
among men of different sexual practices. Seroprevalence of HPV 6, 11, 16 and/or 18 
was twice as high among MSM and MSMW compared to MSW. Likewise, 
seroprevalence of individual HPV types was two fold or higher among MSW and MSMW.  
Our findings suggest that the predominant predictors of seropositivity to HPV 6, 
11, 16 and 18 are age and same-sex sexual behaviors. Seroprevalence increased 
significantly with age among young-to-middle-aged men, and declined among older men 
for HPV 6 and 11, whereas plateau for HPV 16, and continued to rise for HPV 18. MSM, 
compared to MSW, more likely to be seropositive to HPV 16 or 18. Similarly, men who 
practiced same-sex anal sex, compared to those who did not, were significantly more 
likely to be seropositive to HPV 6, 11, 16 and 18, respectively. The fluctuation of 
seroprevalence with age probably reflects age-related immune response and sexual 
behavior pattern over one’s life span. The higher seroprevalence associated with the 
practice of same-sex anal sex is likely explained by the higher likelihood of simultaneous 
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HPV infections (oral, genital and anal) at multiple anatomic sites among MSM and 
MSMW. The finding may also imply that infection at mucosal epithelium is more likely to 
induce an immune response than infection at keratinized epithelium.  
Also of the primary interest in this dissertation was the relationship between 
serum antibodies and subsequent risk of infection with the same HPV type or genetically 
related and un-related HPV types. Among 276 men free of HPV 16 at enrollment in 
Tucson, We did not detect statistically significant associations between the baseline 
serum antibodies to HPV 16 and/or 18 and subsequent risk of infection with 
homogeneous HPV types or related-HPV types. Of 2187 men residing in three countries 
who tested HPV 16 negative at enrollment, the risk of incident HPV 16 infection 
appeared to be lower in seropositive men compared to seronegative men within the first 
year of study period. The risk difference was more apparent among MSM and MSMW.  
So was the risk difference for 6-month persistent HPV 16 infection within the first year. 
However, data indicated that detection of HPV 16 serum antibodies at the baseline did 
not predict a man’s risk of acquiring HPV 16 infection over time.  
The findings of this dissertation support strategic vaccination of males as an 
effective preventive measure for HPV-related diseases and cancers in men and their 
sexual partners, men and women alike. Our data also provide important estimates of 
population exposure to vaccine HPV types for future studies modeling potential vaccine 
impact and vaccine cost effectiveness in men to provide further guidance for male 
vaccination policy. 
Among many possible paths the future research may take, it is of primary interest 
for us to gain a better understanding of the natural history of humoral immune response 
to HPV infection.  Prospective studies with repeated assessment of participant sexual 
behaviors, HPV DNA and serum antibody status and a multiple-year follow-up are 
needed to observe the lag time between the detection of type-specific incident HPV 
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infection and the detection of serum antibodies corresponding to the specific HPV type, 
to estimate type-specific seroconversion rates, to determine the longevity of type-specific 
serum antibodies in men, and to investigate factors associated with type-specific serum 
antibody development and persistence. Furthermore, prospective studies with similar 
design are also essential to explore potential influence of serum antibody presence on 
acquisition and clearance of infection with homogeneous HPV type and genetically 
related HPV types in men. The studies need to take into account various durations of 
serum antibody presence, and examine the associations between serum antibody 
detection and HPV acquisition and clearance by duration of antibody presence to 
determine if persistence of serum antibody plays a role in conferring protection.  
As the choices made by individual studies of VLP-based immunoassay, control 
sera, and cutoff points could limit valid comparison of serum antibody measurements 
across studies, future studies focusing on establishing standard reference sera and 
determining correlates of commonly used VLP immunoassays could provide a 
comprehensive platform for interpretation of findings on serum antibody detection and 
associated factors across studies, and to advance our understanding of humoral 
immune response to HPV infection.  
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APPENDIX A: LITERATURE REVIEW 
 
1. SEROEPIDEMIOLOGY OF HPV IN MEN 
1.1. Introduction 
Serological studies on HPV infection have been hampered by the difficulty of 
obtaining HPV virions from cell cultures to use as antigen targets for serological assay 
until recent years. This challenge was met through the invention of virus-like particle 
(VLP) technologies. VLPs are empty HPV viral capsids that contain no viral particles but 
appear morphologically identical to and contain the major neutralizing epitopes of the 
native HPV virion [1, 2]. Using recombinant DNA technology, the structural protein L1 or 
L2 in HPV viral capsid is expressed as virus-like particles (VLPs) in viral vectors such as 
vaccinia virus or baculovirus; the viral vectors are used to infect insect or mammalian 
cells to produce large quantities of VLPs, which formed the basis for VLP-based 
enzyme-linked immunosorbent assay (ELISA) for HPV antibody testing. Anti-HPV serum 
IgG antibodies detected by VLP-based assays are type-specific [3-5] and are most 
commonly used in HPV serology studies. The first L1 VLP-based assay that correlated 
with type-specific detection of HPV DNA was established in 1994 [6]. Since then, the use 
of VLP-based ELISA has led to our better understanding of serum antibody response to 
HPV infections. 
1.2. Serum Antibody Response to Human Papillomavirus Infection 
Serum antibodies elicited by natural HPV infection reflect cumulative exposures 
to HPV over time and across anatomic sites. The majority of type-specific 
seroconversion is observed within one year following incident HPV DNA detection, as 
evidenced in natural history studies of serum antibodies among women [7-10]. 
Andersson-Ellstrom and colleagues followed 98 adolescent girls aged 15-17 every 6 
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months for 2 years and observoed that of 6 girls who were initially seronegative and 
DNA negative, and who serocnverted during the follow-up, 5 tested positive for incident 
HPV 16 DNA at the visit prior to seroconversion [9]. Similarly, a median time of 8.3 
months from detection of incident HPV 16 DNA to seroconversion was observed among 
28 female university students who acquired HPV 16 during the follow-up in the study of 
Ho et al [8]. Carter et al reported that the median time to seroconversion for 56 women 
with incident HPV 6, 16 or 18 infection was 11.7, 11.8 and 12.6 months, respectively, 
among a cohort of 588 female university students aged 18-20 [7].  
Anti-HPV serum antibodies appear to be stable over time and remain detectable 
even after a decade [10-13]. Not all individuals challenged by natural exposure to HPV 
develop antibody response detectable by current serology assays in the months 
following detection of infection [7, 8]. Carter et al observed that few seroconversions 
occurred after 18 months following incident HPV detection and the 18-month 
seroconversion rate was 68.8%, 59.5%, and 54.1% for incident HPV 6, 16, and 18, 
respectively [7]. A 12-month cumulative incidence of seroconversion of 56.7% (95% CI, 
34.0–79.4) was reported by Ho et al [14]. Although issues like differential seroconversion 
measurable by VLP-based assay following DNA detection of different HPV types, and 
unknown longevity of anti-HPV serum antibodies could limit faithful translation, HPV 
serology remains a useful means for estimating cumulative HPV exposures in the 
population.  
Limited number of studies have investigated prevalence of serum antibodies in 
men, with a majority of them evaluating HPV 16 seroprevalence. Seroprevalence of HPV 
16 ranges from 5.1% to 47.5% depending on the study population examined, and choice 
of serological assay, control serum and cut-off point for determining seropositivity. 
Hagensee et al reported HPV 16 seroprevalence of 47.4% among 101 HIV-negative and 
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42.2% among 154 HIV-positive homosexual or bisexual men who participated in Seattle-
King County Department of Public Health AIDS Prevention Project [15]. A capture ELISA 
was applied and a cut-off point determined using (1) similarly tested sera from a group of 
women without sex partners and evidence of HPV 16 DNA; and (2) a population-based 
maximum likelihood method. Using a similar assay and a cut-off point chosen based on 
similarly run sera from children <10 years of age with no evidence of HPV infection, 
Slavinsky et al observed a HPV 16 seroprevalence of 36.1% among 687 STI clinic 
attendees in New Orleans [16]; and Thompson and colleagues estimated a 
seroprevalence of 18.7% among 786 HIV-negative, heterosexual men attending 5 public 
STI clinics in the U.S. [17]. Using a direct ELISA assay, seropositivity to HPV 16 among 
404 Jamaican male STI clinic attendees was 29% as determined by Strickler et al [18], 
and 9-32% among 219 Danish and 11-35% among 88 Greelandic male STI clinic 
patients in the study of Svare et al using various cut-off points [19]. 
Seroprevalence appeared to be consistently lower in population- and community-
based studies than clinic-based studies. In general, the direct-binding ELISA assay 
showed higher sensitivity for serum antibody detection than the single-epitope 
competitive ELISA assay when applied in similar populations. HPV 16 seropositivity was 
found in 13.0% of 3110 male participants of National Health and Nutrition Examination 
Survey (NHANES 1991-94) in which a direct-binding ELISA assay and a cut-off value 
was chosen on the basis of optimal sensitivity and specificity [20]; whereas seropositivity 
was observed in 5.1% of 2128 NHANES 2003-2004 male participants using a 
multiplexed, competitive immunoassay and a predetermined cut-off value [21]. However, 
it was possible that besides the assay difference, other factors such as cohort effect 
might have contributed to the difference in seroprevalence between the two NHANES 
populations. Likewise, approximately 12% of 462 male residents aged 18-40 in two U.S. 
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cities were HPV 16 seropositive as determined by a capture ELISA assay [22] and a cut-
off point estimated using similarly tested sera from children <10 years old with no prior 
history of warts. In comparison, using a direct ELISA assay and a similar method to 
determine the cut-off value, Kreimer et al detected a HPV 16 seroprevalence of 14.1% 
among 340 men aged 18-76 participating in an oral cancer screening program and an 
oral HPV prevalence study [23].  
Seroprevalence of other oncogenic genital HPV types evaluated in men include 
HPV 18, 31, 33, 45, 52 and 58. Seroprevalence of HPV 18, 31, 33 and 45 were 11.1%, 
7.4%, 13.0% and 11.1% among 54 male participants of an epidemiologic study in South 
Africa using a direct ELISA assay [24]. Seroprevalence were 18.8% and 9.7% for HPV 
18 and 33 among 340 men in the study of Kreimer et al [23]. Using a competitive ELISA 
assay, Dunne et al and Markowitz et al reported a seroprevalence of 5.4% and 1.5% for 
HPV 18, respectively [21, 22]. 
Few studies have evaluated serum antibodies to HPV 6 or 11 detectable by VLP-
based assays. The seroprevalence was 40.6% for HPV 6 among HIV-negative and 
31.8% among HIV-positive homosexual and bisexual men [15]. Seroprevalence of HPV 
6/11 was 31.6% among STI clinic attendees in the U.S. [16], and 9.7% among residents 
of two U.S. cities using capture ELISA [22]. In comparison, HPV 11 seroprevalence was 
4.7% in NHANES 1991-1994 participants with a direct ELISA assay [25], and 2.0% in 
HANES 2003-2004 participants with a multiplexed, competitive assay [21].  
1.3. Risk Factors Associated with Seroprevalence in Men 
A growing body of literature has examined factors associated with HPV 
seroprevalence in women determined by VLP-based immunoassay, In contrast, little is 
known about factors associated with seroprevalence in men. Despite differences in 
study populations examined, choice of serological assays, control population and cut-off 
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points selected to determine seropositivity, evidence that emerges from the literature in 
men suggests that age, lifetime and recent number of sex partners and the practice of 
same-sex sexual intercourse are the most consistent predictors of HPV 16 seropositivity 
in men.  
In a cross-sectional study that investigated factors associated with HPV 16 
seropositivity among 219 HIV-negative Danish men and 88 Greenlandic men attending 
STI clinics in Copenhagen and Nuuk, risk of seropositivity was found to be significantly 
associated with increasing number of lifetime sex partners, a self-reported history of any 
STI, and sexual preference [19] in Denmark but not in Greenland. The risk of 
seropositivity was higher for men with ≥40 partners (OR, 2.8; 95% CI: 1.0–7.7) 
compared to men with 1–19 partners, for those with a self-reported history of any STI 
(OR, 2.6; 95% CI: 1.1-6.3), and for bisexual men compared with heterosexual men (OR, 
3.0; 95% CI: 1.2-7.6). Strickler and colleagues demonstrated that older age (p<0.05), 
greater lifetime number of sexual partners (p<0.01) and longer years of sexual activity 
(p<0.05) were each significantly associated with seropositivity to HPV 16 among 
Jamaican STI clinic attendees [18]. In addition, sexual behavior in the past year 
including tears or bruises of the penis during sex (p=0.01), a greater number of sexual 
partners (p=0.01) and less regular use of condoms (p=0.05) were also independently 
associated with HPV 16 seroprevalence. 
Hagensee et al observed that among HIV-seronegative men participating in an 
AIDS Prevention Project, having >50 lifetime male sex partners (OR, 3.8; 95% CI, 1.6-
9.0) was significantly associated with detection of antibodies to HPV-16; and age >35 
(OR, 2.0; 95% CI, 0.8-4.7) was suggestive of an independent association [15]. Slavinsky 
et al confirmed the association of HPV 16 serum antibody detection with age >30 (OR, 
2.55; 95% CI: 1.50-4.40) and a history of STI (syphilis; OR, 1.60; 95% CI: 1.50-2.43) 
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among a cohort of STI clinic patients [16]; Whereas Thompson and colleagues observed 
in a similar group of men that Hispanic men compared to White men (OR, 2.0; 95% CI: 
1.0–3.8]), men aged >20 compared to those aged ≤20 (OR, 3.4; 95% CI: 1.4–7.8), and 
men having had 1 occasional sex partner in preceding 3 months compared to those with 
none (OR, 1.7; 95% CI: 1.1–2.8) were more likely to test seropositive for HPV 16 [17].  
While lower seroprevalence of HPV 16 was detected among nationally 
representative samples of men and community male residents than in the high-risk male 
populations, factors associated with detection of anti-HPV 16 serum antibodies in 
population-based and community-based studies resemble those detected in STI clinic-
based studies. Data from the survey of NHANES 1991-1994 participants indicated that 
men who had first intercourse at age 18 or younger (OR, 2.5; 95% CI: 1.7–4.0), had a 
history of same-sex sexual intercourse (OR, 6.1; 95% CI: 2.7–14.0), or had ≥10 year of 
sexual activities (OR, 3.6; 95% CI: 1.8–7.3) were more likely to be HPV 16 seropositive 
[20]. Age ≥30 (OR, 1.9; 95% CI: 0.9–4.1) was suggestive, but was not statistically 
significant. In addition, there appeared to be an interaction between race and residence, 
with urban non-Hispanic White men (OR, 2.8; 95% CI: 1.6–5.0) and Black men (OR, 2.1; 
95% CI: 1.2–3.5) at higher risk of HPV 16 seropositivity [20]. In comparison, age and 
lifetime number of sex partners were positively and significantly associated with 
seroprevalence of HPV 16 and/or 18 in the survey of NHANES 2003-2004 male 
participants [21]. Similar associations were also reported by Dunne et al among 
predominantly heterosexual men where older age (OR, 6.8; 95% CI: 3.7, 12.8), a greater 
number of female partners in the last 3 months (1 vs. 0 partner: OR, 4.5; 95% CI: 1.6-
12.6 ; and >1 vs. 0 partner: OR, 5.3; 95% CI: 1.8-15.8) and current smoking (OR, 1.9; 
95% CI: 1.1-3.2) were independently associated with higher seroprevalence of HPV 6, 
11, 16 and/or 18 [22]. In addition, Kreimer et al confirmed that seroprevalence of HPV 
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16, 18 and/or 33 was significantly associated with ever having same-sex oral sex (OR, 
2.9; 95% CI: 1.2–7.1) as well as participant HIV serostatus (OR, 2.1; 95% CI: 1.2–3.9) 
[23]. 
2. THE ROLE OF NATURAL IMMUNITY IN THE NATURAL HISTORY OF HPV 
INFECTION 
2.1. Association of serum antibodies with subsequent risk of HPV acquisition 
Few serology studies in women have assessed whether anti-HPV serum 
antibodies, induced by natural infection, were effective in protecting against subsequent 
infection with homologous or phylogenetically related HPV types. Findings from these 
studies have been inconsistent [26-28]. Viscidi et al investigated the risk of incident HPV 
16 infection 5-7 years following detection of type-specific serum antibodies to HPV 16, 
18 and 31 at enrollment among 7046 women enrolled in the Guanacaste Natural History 
Study using a direct ELISA assay, and failed to detect a significant difference in the risk 
of subsequent infection between baseline seropositive and seronegative women for any 
of these HPV types. Likewise, Trottier et al investigated the risk of incident HPV 16 
infection by baseline serum antibody status among 1,902 women enrolled in the Ludwig-
McGill cohort who were HPV 16 negative at baseline and followed every 4-6 months for 
up to 10 years using a similar assay [28]. The authors observed that the incidence rate 
was highest among women with the highest level of HPV-16 antibodies at baseline and 
there was no significant difference in incidence rates between women with the lowest 
antibody titers and those with the highest antibody titers (Lowest tertile 1.6 [95% CI: 1.3–
2.1] vs. Highest tertile 2.1 [95% CI: 1.7–2.6]).  
In contrast, Ho et al monitored 608 female college students with HPV16 antibody 
measured annually and HPV DNA measured every six months for a maximum of 3 
years, and observed a protective effect of serum antibodies against incident infection 
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with HPV 16 (RR, 0.49; P=0.037) and its related types (P = 0.010) among young women 
who had persistent high antibody titer at ≥2 visits prior to the detection of infection [26]. 
Likewise, a protective effect was observed by Velicer et al among women aged 24-34 
enrolled in the placebo arm of a HPV vaccine trial using cLIA, as evidenced  by a lower 
incidence of HPV 6/11/16/18 infection and 6-month persistent infection among baseline 
seropositive women compared to seronegative women (incident infection: 1.0 [0.31–
2.23] vs. 5.7 [4.68–6.84] per 100 woman-years; 6-month persistent infection: 0.4 [0.05–
1.37] vs. 2.5 [1.89–3.35] per 100 woman-years) [29] 
2.2. Gender Difference in Seroprevalence 
It has been noted in a number of HPV serology studies that men and women 
appear to respond to HPV infection differently. Despite the higher DNA prevalence and 
risky sexual behaviors observed in men, consistently lower antibody titers and a lower 
seroprevalence were observed in men compared to their female counterparts [17, 19-21, 
23, 30]. The gap in HPV 16 seroprevalence between men and women ranges from 10-
40%. In spite of variation in assays used, a 10% difference was observed in both studies 
of Stone et al [20] and Markowitz et al [21] among NHANES participants. The difference 
was 12% among STI clinic attendees in 5 U.S. cities [17] and 28% among oral cancer 
screening program and oral HPV study participants in Baltimore, U.S. [23]. In contrast, 
an up to 40% difference was detected among STI clinic patients in Denmark and 
Greenland [19]. These gender-related differences are likely an indication of differential 
immune responses induced by infection at keratinized epithelium versus that at mucosal 
epithelium. 
 To date, no study has evaluated the role of serum antibodies in prevention of 
subsequent HPV infection in men. This dissertation will be the first to explore potential 
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associations and to shed lights on the role of natural immunity in the natural history of 
HPV infection in men. 
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